Biotec Pharmacon receives promising interim results from animal study
The results showed that SBG successfully can be mixed with different gel agents, and results also indicate that such mix improves the wound healing capability of the product. The best results were obtained with a combination of 2% SBG and carboxymethylcellulose (CMC), the latter being used in several of the commercial wound treatment hydrogels on the market, like Intrasite from Smith & Nephew and in the wound healing drug Regranex. This combination product of SBG and CMC induced statistically significant improved wound healing from day 12 and onwards throughout the study (day 24) only paralleled by the positive control. The results also confirm that such a SBG based product performs better than the other commonly used hydrogels containing CMC tested and also methylcellulose that was the placebo of the clinical studies.
As earlier reported, it was observed that a pure 2% aqueous solution of SBG when stored in aluminum tubes or polyethylene ampoules, were very sensitive to accelerated storage conditions as seen by early fragmentation of the gel. These two container types were accordingly chosen for the ongoing stability program to secure rapid progress in testing the new formulations. Preliminary data from the accelerated stability studies have so far indicated that the stability of SBG can be significantly improved. Either by increasing the concentration of SBG alone above 2% in water, resulting in a more solid gel, or by mixing SBG with an additional gel agent like CMC.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.